HROW · Harrow, Inc.
$31.19
+0.71 (+2.33%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$1.24B
Shares
37.49M
Volume · Oct 5
587.39K
Avg daily vol (3M)
564.13K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$30.48
Open$30.83
Day$30.15–30.97
52W close$29.03–54.80
Avg vol 30d538K
Short int7.5M · 20.0% float · 15.7d
Short vol61%
Last earningsAug 11, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 10
Up next
Next earnings call
Nov 12, 2026
Est · unconfirmed
· in 5 wks
filed Aug 10, 2026
call held Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$275.59M
Trailing 12 months
Net income (TTM)
−$37.23M
Trailing 12 months
Revenue growth YoY
+10.9%
Year over year
Operating margin
-1.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
0.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-3.9%
Year over year · fewer shares
Price change (1Y)
-36.1%
Trailing year
Short interest
20.0%
Latest settlement · 15.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−24%
below
Price vs 50-day avg
−18%
below
RSI (14)
26
oversold
MACD trend
Negative
52-week position
6%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−20%
trailing
6-month return
−18%
trailing
YTD return
−38%
this year
Relative strength
−30%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $37 › 200d $40 — 200d above 50d
Institutional flow
Accumulating
1 of 224 funds reported for Sep 30 · net +29 sh shares
Insider flow
Distributing
Net -$450.0K over 90 days · 100% sells
Short interest
Rising
19.98% of float · ▲ +10.5% MoM · 15.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
224 holders — near 3-yr high, broad support
Squeeze score
71
high risk · 0–100
Fundamentals
Revenue growth
+36%
Y/Y
Gross margin
75%
contracting
EPS growth
+71%
Y/Y
Free cash flow
$43.0M
Balance sheet
$177.1M
net debt
Quant / Vol
risk profile
Volatility
64%
annualized · 1-yr
Max drawdown
−47%
past year
ATR
4.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 10, 2026
full-year 2026
Full-year 2026 financial guidance
Initiated
$350M – $365M
prior FY $272.3M
midpoint +31.3% Y/Y
Adjusted EBITDA
Non-GAAP
Initiated
$80M – $100M
2027
TYRVAYA revenue
at least $30M
Guided vs delivered
· last 2 settled
Revenue
2024
guided at least $180M
$199.61M
In line
Revenues
2023
guided $129M – $136M
$130.19M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−24%
Bearish
Price vs 50-day avg
−18%
Bearish
RSI (14)
26
Neutral
MACD trend
Negative
Bearish
52-week position
6%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $37 › 200d $40 — 200d above 50d
Institutional flow
Accumulating
1 of 224 funds reported for Sep 30 · net +29 sh shares
Insider flow
Distributing
Net -$450.0K over 90 days · 100% sells
Short interest
Rising
19.98% of float · ▲ +10.5% MoM · 15.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
224 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $29
Now $30 · 6%
Range high $55
vs 200-day avg -24%
vs 50-day avg -18%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$1,232,000 | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP GAAP net (loss) income -$17,270,000
+$3,788,000 Stock-based compensation and expenses
+$6,263,000 Interest expense, net
+$0 Income tax expense
+$460,000 Depreciation
+$5,527,000 Amortization of intangible assets
+$0 Investment loss, net
+$0 Other expense, net
= Adjusted EBITDA -$1,232,000
|
|||
| Branded TRx market share | 14.6% | Q2 2026 | — |
| Compounding gross margin | 52.8% | Three Months Ended June 30, 2026 filing | — |
| Reorder rate | 85.5% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HROW
this stock
Harrow, Inc.
|
$1.24B | -37.8% | +36.4% | — | 20.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.5% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.7% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -13.0% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HROW | -7.8% | -20.3% | -17.8% | -1.0% | -37.8% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -7.6% | -19.9% | -30.0% | -2.0% | -50.7% |